Merry Life Biomedical Company Launches Global Phase II Clinical Trial for Alzheimer's Disease Treatment

Strategic Insights -

Merry Life Biomedical Company has announced the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). The multicenter trial will enroll 210 patients with mild cognitive impairment (MCI) or mild dementia across the United States, Sweden, and Taiwan, with primary endpoints including neuropsychological assessments, blood biomarkers, brain MRI, amyloid PET scans, and ApoE genotyping. The trial has received FDA approval and is expected to initiate in April 2026, conducted by Syneos Health CRO.

Key Takeaways:

  • The Phase II clinical trial for TML-6 will be a 12-month study enrolling 210 patients with mild cognitive impairment (MCI) or mild dementia across 19 sites in the United States, Sweden, and Taiwan.
  • The trial will evaluate the safety, tolerability, and efficacy of TML-6 in patients with early-stage Alzheimer's disease (AD), with primary endpoints including neuropsychological assessments, blood biomarkers, brain MRI, amyloid PET scans, and ApoE genotyping.
  • TML-6 is designed to address multiple mechanisms underlying AD, including anti-oxidative effects, autophagy function, anti-amyloid accumulation, and anti-inflammatory effects.
  • The trial has received FDA approval and is expected to initiate in April 2026, conducted by Syneos Health CRO.
  • Merry Life Biomedical Company is a Taiwan-based biotechnology company focused on developing innovative therapies for neurodegenerative and age-related diseases.
  • The company's strong preclinical and clinical profile of TML-6 holds promise as both a monotherapy and in combination with anti-amyloid biologics for AD treatment.

Statistics:

  • 210 patients will participate in the Phase II clinical trial.
  • The trial will be conducted at 19 sites across the United States, Sweden, and Taiwan.
  • The trial is expected to initiate in April 2026.
  • Merry Life Biomedical Company has received FDA approval for the trial.

Sources:

  • Merry Life Biomedical Company, Ltd. (2025, June 12). Merry Life Biomedical Company Announces Launch of Global Phase II Clinical Trial for TML-6, a Novel Oral Small Molecule Drug for Treatment of Early-Stage Alzheimer's Disease.
  • Merry Life Biomedical Company, Ltd. (2025, May 13). Merry Life Biomedical Company Completes Type C FDA Consultation for Phase 2 Trial Design of TML-6, a Novel Oral Small Molecule Drug for Alzheimer's Disease Treatment.